Affymetrix's Q3 Revenues Increase 4 Percent; Shares Sink on Estimates Miss | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market Wednesday that its third-quarter revenues increased 4 percent while its net loss fell sharply.

However, its top- and bottom-line results missed analysts' consensus estimates. In early Thursday trade on the Nasdaq, Affy's shares traded down 18 percent at $7.25.

The Santa Clara, Calif.-based firm reported total revenues of $78.2 million for the three-month period ended Sept. 30, up from $75.2 million for the third quarter of 2008. Analysts, on average, had expected revenues of $80.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.